Patents by Inventor Brian Troy Frederick

Brian Troy Frederick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10941183
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 9, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Publication number: 20210009638
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: August 24, 2020
    Publication date: January 14, 2021
    Inventors: Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan
  • Publication number: 20200361992
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 19, 2020
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Brian Troy FREDERICK, Jie ZHANG, Adam STEPHENSON, Mark Leslie SMYTHE, Roopa TARANATH, David LIU
  • Patent number: 10787490
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases, are described.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 29, 2020
    Assignee: Protaganist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 10729676
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: August 4, 2020
    Assignee: Protagonist Theraputics, Inc.
    Inventors: Sampath Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu, Mukund M. Mehrotra
  • Publication number: 20200239523
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Application
    Filed: January 28, 2020
    Publication date: July 30, 2020
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Patent number: 10626146
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 21, 2020
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Publication number: 20200040037
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: July 12, 2019
    Publication date: February 6, 2020
    Inventors: Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan
  • Publication number: 20200017566
    Abstract: The present invention provides novel hepcidin analogues, and related methods of using these hepcidin analogues to treat or prevent a variety of diseases and disorders, including iron overload diseases such as hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: June 12, 2019
    Publication date: January 16, 2020
    Inventors: Gregory Thomas BOURNE, Mark Leslie SMYTHE, Brian Troy FREDERICK, Simone VINK
  • Patent number: 10501515
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 10, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20190337983
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 7, 2019
    Inventors: Ashok Bhandari, Gregory Thomas BOURNE, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 10442846
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 15, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20190300590
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: July 15, 2016
    Publication date: October 3, 2019
    Inventors: Ashok BHANDARI, Gregory BOURNE, Xiaoli CHENG, Brian Troy FREDERICK, Jie ZHANG, Dinesh V. PATEL, David LIU
  • Publication number: 20190231746
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Application
    Filed: March 6, 2019
    Publication date: August 1, 2019
    Inventors: Sampath-Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Publication number: 20190185535
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 20, 2019
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20190185536
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 20, 2019
    Inventors: Mark Leslie SMYTHE, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Patent number: 10278957
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 7, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Sampath Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Publication number: 20190076400
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Application
    Filed: September 11, 2018
    Publication date: March 14, 2019
    Inventors: Sampath Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Patent number: 10196424
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Publication number: 20190016756
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 17, 2019
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu